Denver, Colo. - Neuroendocrine cancer is exceedingly difficult to manage and unlikely to be cured, but researchers intend to slow progression of these tumors and aid survival by personalizing patient ...

Peptide receptor radionuclide therapy (PRRT) with lutetium dotatate is a treatment for well-differentiated neuroendocrine tumors that the U.S. Food and Drug Administration approved in 2018, but ...

Peptide receptor radionuclide therapy (PRRT) and lutetium dotatate are treatments for well-differentiated neuroendocrine tumors. Clinicians have lacked a metric for predicting its benefit on an ...

PITTSBURGH (KDKA) -- Jackie Lapisardi was one of the lucky ones. "I was having a scan for something else, and they discovered something on my pancreas." It was cancer -- a rarer type called ...

For 177Lu-PRRT, the mean number of cycles administered was 5.3 ± 2.5; for 90Y-PRRT, the mean number of cycles administered was 5.5 ± 2.6. Median overall survival was 79 months, but 32 percent of the ...

The peptide receptor radionuclide therapy (PRRT) market is projected to be valued at approximately USD 591.83 million in 2023 and is expected to expand significantly, reaching USD 1,300 million by ...

Perspective Therapeutics' novel alpha emitter PRRT shows promise in early trials, with manageable toxicity and durable disease control in GEP-NETs and melanoma. Strong cash position allows CATX to ...

"So far, the majority of PRRT treatments have been administered one-size-fits-all, meaning every patient receives about the same amount of radioactivity," said Jean-Mathieu Beauregard, MD, assistant ...